296 related articles for article (PubMed ID: 36833320)
1. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
Nakajima R; Zhao L; Zhou Y; Shirasawa M; Uchida A; Murakawa H; Fikriyanti M; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833320
[TBL] [Abstract][Full Text] [Related]
2. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.
Nakajima R; Deguchi R; Komori H; Zhao L; Zhou Y; Shirasawa M; Angelina A; Goto Y; Tohjo F; Nakahashi K; Nakata K; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
Biochem Biophys Res Commun; 2023 Jun; 663():154-162. PubMed ID: 37141667
[TBL] [Abstract][Full Text] [Related]
3. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs.
Kurayoshi K; Ozono E; Iwanaga R; Bradford AP; Komori H; Ohtani K
Biochem Biophys Res Commun; 2014 Jul; 450(1):240-6. PubMed ID: 24893334
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts.
Kitamura H; Ozono E; Iwanaga R; Bradford AP; Okuno J; Shimizu E; Kurayoshi K; Kugawa K; Toh H; Ohtani K
Genes Cells; 2015 Sep; 20(9):739-57. PubMed ID: 26201719
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of the CDK inhibitor p21
Kurayoshi K; Shiromoto A; Ozono E; Iwanaga R; Bradford AP; Araki K; Ohtani K
Biochem Biophys Res Commun; 2017 Jan; 483(1):107-114. PubMed ID: 28042030
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts.
Ozono E; Komori H; Iwanaga R; Tanaka T; Sakae T; Kitamura H; Yamaoka S; Ohtani K
Genes Cells; 2012 Aug; 17(8):660-72. PubMed ID: 22702391
[TBL] [Abstract][Full Text] [Related]
7. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity.
Ozono E; Komori H; Iwanaga R; Ikeda MA; Iseki S; Ohtani K
Genes Cells; 2009 Jan; 14(1):89-99. PubMed ID: 19077036
[TBL] [Abstract][Full Text] [Related]
8. The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity.
Kurayoshi K; Okuno J; Ozono E; Iwanaga R; Bradford AP; Kugawa K; Araki K; Ohtani K
Biochem Biophys Res Commun; 2017 Jan; 482(4):784-790. PubMed ID: 27888102
[TBL] [Abstract][Full Text] [Related]
9. Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression.
Zhou Y; Nakajima R; Shirasawa M; Fikriyanti M; Zhao L; Iwanaga R; Bradford AP; Kurayoshi K; Araki K; Ohtani K
Biology (Basel); 2023 Dec; 12(12):. PubMed ID: 38132337
[TBL] [Abstract][Full Text] [Related]
10. Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes.
Komori H; Goto Y; Kurayoshi K; Ozono E; Iwanaga R; Bradford AP; Araki K; Ohtani K
Sci Rep; 2018 May; 8(1):8438. PubMed ID: 29855511
[TBL] [Abstract][Full Text] [Related]
11. Apaf-1 is a transcriptional target for E2F and p53.
Moroni MC; Hickman ES; Lazzerini Denchi E; Caprara G; Colli E; Cecconi F; Müller H; Helin K
Nat Cell Biol; 2001 Jun; 3(6):552-8. PubMed ID: 11389439
[TBL] [Abstract][Full Text] [Related]
12. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action.
Yamasaki L
Biochim Biophys Acta; 1999 Mar; 1423(2):M9-15. PubMed ID: 10214348
[TBL] [Abstract][Full Text] [Related]
13. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
14. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the Arf/p53 tumor surveillance network by E2F.
Iaquinta PJ; Aslanian A; Lees JA
Cold Spring Harb Symp Quant Biol; 2005; 70():309-16. PubMed ID: 16869767
[TBL] [Abstract][Full Text] [Related]
16. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression.
Lukas J; Petersen BO; Holm K; Bartek J; Helin K
Mol Cell Biol; 1996 Mar; 16(3):1047-57. PubMed ID: 8622649
[TBL] [Abstract][Full Text] [Related]
17. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.
Ofir M; Hacohen D; Ginsberg D
Mol Cancer Res; 2011 Apr; 9(4):440-7. PubMed ID: 21454377
[TBL] [Abstract][Full Text] [Related]
18. JNK activation is regulated by E2F and promotes E2F1-induced apoptosis.
Bashari D; Hacohen D; Ginsberg D
Cell Signal; 2011 Jan; 23(1):65-70. PubMed ID: 20800677
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas.
Gorgoulis VG; Zacharatos P; Mariatos G; Kotsinas A; Bouda M; Kletsas D; Asimacopoulos PJ; Agnantis N; Kittas C; Papavassiliou AG
J Pathol; 2002 Oct; 198(2):142-56. PubMed ID: 12237873
[TBL] [Abstract][Full Text] [Related]
20. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
Aslanian A; Iaquinta PJ; Verona R; Lees JA
Genes Dev; 2004 Jun; 18(12):1413-22. PubMed ID: 15175242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
